Contrary to expectations, United Spirits' Q1 FY26E outlook too is expected to be soft. As per the management channel feeling in Q1 FY25 ahead of elections shall lead to soft growth.
NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Dolat Capital Report
United Spirits Ltd. over FY23-25 reported modest revenue CAGR of 9.5% (partly aided by Andhra Pradesh) but robust Ebitda/adjusted profit after tax compound annual growth rate of 28/42%.
These have been driven by premiumization, opening of AP and productivity initiatives (mono-cartoons, factory reductions, sourcing etc). United Spirits is likely to face multiple headwinds in FY26 (especially Q2 onwards) on both revenues (Maharashtra, AP forming part of base) and margins (productivity benefits behind).
We thus expect Ebitda/Ebit to decline ~4/5% in FY26E. This shall lead to PE de-rating in our view.
We estimate negative Ebitda impact (vs expectations) of ~Rs 1.5- 2 billion p.a. from Maharashtra alone. We thus reduce our FY26/27E EPS by 13/7% and PE from 60x to 50x standalone FY27E EPS.
Downgrade to ‘Sell’ from ‘Reduce’ with a revised target price of Rs 1,335 (incl. Rs 125 for RCB) vs Rs 1,675 earlier.
Our FY26/27E EPS is ~19/15% lower than consensus. United Spirits is currently trading at 72/59x FY26/27E earnings per share.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
RECOMMENDED FOR YOU
Emcure Pharma Block Deal: Public Shareholder BC Investments To Sell 2.4% Stake


Somany Ceramics Cut To 'Add' As HDFC Securities Sees Limited Upside After Recent Rally


Biocon's Fundraise To Provide Investor Exits Closes Listing Window For Unit


Buy, Sell Or Hold: Cipla, Premier Energies, Bajaj Finance, Tata Motors, Tilaknagar Industries — Ask Profit
